M&T Bank Corp Gilead Sciences, Inc. Transaction History

M&T Bank Corp

$28.6 Billion
Q1 2024

A detailed history of M&T Bank Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 196,477 shares of GILD stock, worth $13.5 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

196,477

Previous 214,702 8.49%

Holding current value

$13.5 Million

Previous $17.4 Million 17.26%

% of portfolio

0.05%

Previous 0.06%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$71.58 - $87.29 $1.3 Million - $1.59 Million	-18,225 Reduced 8.49%	196,477 $14.4 Million
Q4 2023 Feb 06, 2024	SELL	$73.27 - $83.09 $62,792 - $71,208	-857 Reduced 0.4%	214,702 $17.4 Million
Q3 2023 Nov 02, 2023	SELL	$73.94 - $80.67 $712,116 - $776,932	-9,631 Reduced 4.28%	215,559 $16.2 Million
Q2 2023 Aug 09, 2023	SELL	$76.01 - $86.7 $383,166 - $437,054	-5,041 Reduced 2.19%	225,190 $17.4 Million
Q1 2023 May 11, 2023	SELL	$77.31 - $88.08 $451,181 - $514,034	-5,836 Reduced 2.47%	230,231 $19.1 Million

Q4 2022 Feb 13, 2023	BUY	$62.32 - $89.47 $5.07 Million - $7.28 Million	81,415 Added 52.64%	236,067 $20.3 Million
Q4 2022 Feb 13, 2023	SELL	$62.32 - $89.47 $4.49 Million - $6.44 Million	-71,972 Reduced 31.76%	154,652 $13.3 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $546,458 - $624,195	-9,178 Reduced 3.89%	226,624 $13.8 Million
Q2 2022 Aug 05, 2022	SELL	$57.72 - $65.01 $2.07 Million - $2.33 Million	-35,882 Reduced 13.21%	235,802 $13.7 Million
Q1 2022 May 09, 2022	SELL	$57.92 - $72.58 $18.2 Million - $22.8 Million	-314,292 Reduced 53.64%	271,684 $16.2 Million
Q4 2021 Feb 07, 2022	BUY	$64.88 - $73.64 $3.55 Million - $4.03 Million	54,758 Added 10.31%	585,976 $42.5 Million
Q3 2021 Oct 28, 2021	BUY	$67.69 - $73.03 $13.7 Million - $14.8 Million	202,507 Added 61.61%	531,218 $37.1 Million
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $559,741 - $611,597	-8,819 Reduced 2.61%	328,711 $22.6 Million
Q1 2021 May 06, 2021	SELL	$60.0 - $68.46 $496,200 - $566,164	-8,270 Reduced 2.39%	337,530 $21.8 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $3.91 Million - $4.45 Million	-68,950 Reduced 16.62%	345,800 $20.1 Million
Q3 2020 Nov 06, 2020	SELL	$62.1 - $78.08 $1.06 Million - $1.33 Million	-17,062 Reduced 3.95%	414,750 $26.2 Million
Q2 2020 Jul 29, 2020	SELL	$72.34 - $84.0 $19 Million - $22.1 Million	-262,652 Reduced 37.82%	431,812 $33.2 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $7.48 Million - $9.58 Million	-119,455 Reduced 14.68%	694,464 $51.9 Million
Q4 2019 Feb 07, 2020	SELL	$61.62 - $67.78 $2.83 Million - $3.11 Million	-45,892 Reduced 5.34%	813,919 $52.9 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $671,107 - $740,784	-10,736 Reduced 1.23%	859,811 $54.5 Million
Q2 2019 Aug 12, 2019	SELL	$61.87 - $69.38 $585,104 - $656,126	-9,457 Reduced 1.07%	870,547 $58.8 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $7.96 Million - $8.92 Million	127,331 Added 16.92%	880,004 $57.2 Million
Q4 2018 Feb 01, 2019	BUY	$60.54 - $79.0 $9.17 Million - $12 Million	151,545 Added 25.21%	752,673 $47.1 Million
Q3 2018 Nov 09, 2018	SELL	$71.28 - $78.92 $544,507 - $602,869	-7,639 Reduced 1.25%	601,128 $46.4 Million
Q2 2018 Aug 10, 2018	BUY	$64.88 - $75.68 $21.6 Million - $25.2 Million	333,022 Added 120.77%	608,767 $43.1 Million
Q1 2018 May 04, 2018	SELL	$72.84 - $88.8 $863,081 - $1.05 Million	-11,849 Reduced 4.12%	275,745 $20.8 Million
Q4 2017 Feb 06, 2018	SELL	$71.15 - $83.52 $4.52 Million - $5.31 Million	-63,545 Reduced 18.1%	287,594 $20.6 Million
Q3 2017 Nov 13, 2017	SELL	$72.11 - $85.47 $409,152 - $484,956	-5,674 Reduced 1.59%	351,139 $28.5 Million
Q2 2017 Aug 11, 2017	BUY	N/A	356,813	356,813 $25.3 Million

Others Institutions Holding GILD

# of Institutions

1,884

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $86B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account